Phaseline

Companies › Cyllene Therapeutics

Cyllene Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EG110A
Intradetrusor injection for neurogenic detrusor overactivity
–Phase 1Neurogenic Detrusor OveractivityJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06596291EG110APhase 1Neurogenic Detrusor OveractivityNeurologyJun 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.